Last reviewed · How we verify

Roflumilast conventional dosage

Asan Medical Center · FDA-approved active Small molecule

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells.

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells. Used for Chronic obstructive pulmonary disease (COPD) with chronic bronchitis to reduce exacerbations.

At a glance

Generic nameRoflumilast conventional dosage
Also known asDaxas
SponsorAsan Medical Center
Drug classPhosphodiesterase-4 (PDE-4) inhibitor
TargetPDE-4
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

By inhibiting PDE-4, roflumilast prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated cAMP levels in inflammatory cells such as macrophages, neutrophils, and T cells. This elevation suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing airway inflammation and mucus production. The drug is used to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), particularly those with chronic bronchitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: